VRPX OTC
Virpax Pharmaceuticals, Inc.
1W: +0.0%
1M: +11000.0%
3M: +0.0%
YTD: +0.9%
1Y: -55.6%
3Y: -100.0%
5Y: -100.0%
$0.01
+0.00 (+0.00%)
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
Dark Pool
Short Interest
Supply Chain
Income Trends
Revenue
$0
+0.0% ▲
Gross Profit
$0
+0.0% ▲
Operating Income
-$12.1B
-76892.3% ▼
Net Income
-$12.1B
-79344.5% ▼
EPS (Diluted)
$-2836.41
-21769.0% ▼
EBITDA
-$12.1B
-79428.1% ▼
Profit Margins
Year-over-Year Growth
View Full Income Statement
| Line Item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 |
|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 |
| YoY Growth | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% |
| Cost of Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 | $0 |
| Gross Margin | — | — | — | — | — |
| R&D Expenses | $1M | $5M | $11M | $5M | $5.8B |
| SG&A Expenses | $3M | $7M | $11M | $8M | $6.3B |
| Operating Expenses | $4M | $12M | $22M | $16M | $12.1B |
| Operating Income | -$4M | -$12M | -$22M | -$16M | -$12.1B |
| Operating Margin | — | — | — | — | — |
| Interest Expense | $148K | $93K | $0 | $0 | -$104M |
| Income Before Tax | -$4M | -$12M | -$22M | -$15M | -$12.1B |
| Tax Expense | $0 | $0 | $0 | $0 | $0 |
| Net Income | -$4M | -$12M | -$21M | -$15M | -$12.1B |
| Net Margin | — | — | — | — | — |
| EPS (Diluted) | $-9.07 | $-10.37 | $-18.32 | $-12.97 | $-2836.41 |
| EBITDA | $4K | $0 | $0 | -$15M | -$12.1B |
| Shares Outstanding | 494515 | 1M | 1M | 1M | 4M |